Such mechanistic insight is pivotal given that optimal macrophage reprogramming requires simultaneous suppression of pro-inflammatory pathways (e.g., FOXO1) and activation of resolution signals (e.g., PPAR-γ)—a combinatorial regulatory paradigm unexplored in miRNA-mediated colitis therapy. This evidence concerns the gene FOXO1 and colitis.